← Back
NeuroTrials.ai
Neurology Clinical Trial Database

ATTENTION

Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion

Year of Publication: 2022

Authors: Tao C, Nogueira RG, Zhu Y, et al. (ATTENTION Investigators)

Journal: New England Journal of Medicine

Citation: N Engl J Med 2022;387:1361-1372

Link: https://doi.org/10.1056/NEJMoa2206317

Bottom Line

In Chinese patients with acute basilar-artery occlusion presenting within 12 hours (about one-third receiving IV thrombolysis), endovascular thrombectomy roughly doubled the rate of good functional outcome (mRS 0-3) at 90 days and reduced 90-day mortality, at the cost of a 5% risk of symptomatic intracranial hemorrhage and 14% procedural complications.

Major Points

  • Randomized 340 patients (2:1) at 36 centers in China to endovascular thrombectomy plus best medical care versus best medical care alone within 12 hours of estimated basilar-artery occlusion.
  • Primary outcome (mRS 0-3 at 90 days) achieved in 46% (thrombectomy) vs 23% (control) — adjusted rate ratio 2.06 (95% CI 1.46-2.91, P<0.001).
  • Ordinal shift toward better outcome favored thrombectomy (adjusted common odds ratio 2.87, 95% CI 1.84-4.47); mRS 0-2 at 90 days was 33% vs 11% (adjusted rate ratio 3.17, 95% CI 1.84-5.46).
  • 90-day mortality was reduced with thrombectomy (37% vs 55%; adjusted risk ratio 0.66, 95% CI 0.52-0.82).
  • Symptomatic intracranial hemorrhage occurred in 5% of thrombectomy patients vs 0% of controls; procedural complications occurred in 14%, including one fatal arterial perforation.

Design

Study Type: Randomized Controlled Trial

Randomization: 1

Blinding: Open-label with blinded outcome assessment (structured telephone interview by locally certified neurologists or nurses unaware of treatment assignment); central imaging core lab and blinded clinical-event adjudication committee

Enrollment Period: February 21, 2021 - January 3, 2022

Follow-up Duration: 90 days

Centers: 36

Countries: China

Sample Size: 340

Analysis: Intention-to-treat (with prespecified per-protocol supportive analysis); multivariable logistic and linear regression adjusted for age, prestroke mRS, time from onset to randomization, and baseline NIHSS


Inclusion Criteria

  • Age ≥18 years
  • Moderate-to-severe acute ischemic stroke defined as NIHSS ≥10 at time of neuroimaging
  • Basilar-artery occlusion confirmed on CTA, MRA, or DSA within 12 hours of estimated stroke onset
  • Estimated occlusion time = sudden onset of basilar symptoms; for wake-up or unwitnessed strokes, time last seen well (12-hour window)
  • Prestroke modified Rankin scale 0-2 if <80 years, or 0 if ≥80 years
  • PC-ASPECTS ≥6 if <80 years, or ≥8 if ≥80 years
  • Written informed consent from patient or legal representative

Exclusion Criteria

  • Prestroke mRS ≥3 (or ≥1 in patients ≥80 years)
  • Intracranial hemorrhage on baseline neuroimaging
  • PC-ASPECTS <6 (<80 years) or <8 (≥80 years)
  • Complete bilateral thalamic or brain-stem infarction
  • Excessive vascular tortuosity precluding safe endovascular access
  • Mydriasis in both eyes
  • Advanced cancer, bleeding diathesis, or severe anemia
  • Basilar artery patent at trial hospital despite occlusion at referring hospital

Baseline Characteristics

CharacteristicControlActive
Mean Age67.3 ± 10.2 years66.0 ± 11.1 years
Sex - Male72% (82/114)66% (149/226)
Prestroke mRS 1-212% (14/114)11% (25/226)
Median NIHSS (IQR)24 (14-35)24 (15-35)
Median PC-ASPECTS (IQR)10 (8-10)9 (8-10)
Large-artery atherosclerosis37% (42/114)48% (108/226)
Intracranial large-artery atherosclerosis29% (33/114)40% (90/226)
Cardioembolism23% (26/114)20% (46/226)
Undetermined cause40% (46/114)31% (69/226)
IV Thrombolysis34% (39/114) - 31% alteplase, 4% urokinase31% (69/226) - 27% alteplase, 4% urokinase
Proximal basilar occlusion34% (39/114)31% (69/225)
Middle basilar occlusion25% (29/114)28% (62/225)
Distal basilar occlusion35% (40/114)33% (74/225)
V4 vertebral occlusion5% (6/114)9% (20/225)
Median time from stroke onset to randomization (IQR)4.9 hours (3.5-7.0)5.1 hours (3.6-7.2)
Median stroke onset to groin puncture (IQR)5.6 hours (3.5-7.5)
Median stroke onset to revascularization (IQR)6.9 hours (5.0-8.8)
Final TICI 2b-393% (208/223)
General anesthesia56% (124/223)

Arms

FieldThrombectomyControl
InterventionEndovascular thrombectomy (stent retriever, thromboaspiration, balloon angioplasty, stent deployment, intraarterial alteplase/urokinase, or combinations at operator discretion) added to best medical care including IV thrombolytics/antiplatelets/anticoagulation per guidelinesBest medical care alone (IV thrombolytics, antiplatelets, anticoagulation per national/institutional guidelines; IV thrombolysis for those arriving <4.5 hours)
DurationSingle procedure with 90-day follow-up90-day follow-up

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Good functional status (modified Rankin scale 0-3) at 90 daysPrimary23% (26/114)46% (104/226)Rate ratio 2.06 (adjusted)<0.001
Excellent functional outcome (mRS 0-2) at 90 daysSecondary11% (12/114)33% (75/226)Rate ratio 3.17 (95% CI 1.84-5.46)Not reported (not adjusted for multiple comparisons)
Ordinal shift in mRS at 90 days (better outcome)SecondaryMedian mRS 6 (IQR 4-6)Median mRS 4 (IQR 2-6)Common odds ratio 2.87 (95% CI 1.84-4.47)Not reported (not adjusted for multiple comparisons)
Median NIHSS at 24-72 hoursSecondary30 (IQR 15-38)21 (IQR 7-35)Beta coefficient -5.94 (95% CI -8.71 to -3.18)Not reported (not adjusted for multiple comparisons)
Median NIHSS at 5-7 days or dischargeSecondary35 (IQR 11-41)16 (IQR 4-36)Beta coefficient -8.64 (95% CI -12.01 to -5.27)Not reported (not adjusted for multiple comparisons)
Barthel Index 95-100 at 90 daysSecondary13% (15/114)34% (77/226)Rate ratio 2.60 (95% CI 1.60-4.21)Not reported (not adjusted for multiple comparisons)
EQ-5D-5L score at 90 days (median)Secondary0 (IQR 0-0.12)0.12 (IQR 0-0.89)Beta coefficient 0.25 (95% CI 0.15-0.34)Not reported (not adjusted for multiple comparisons)
Basilar artery patency at 24-72 hours (CTA/MRA)Secondary38% (26/69)91% (147/161)Rate ratio 2.58 (95% CI 1.89-3.51)Not reported (not adjusted for multiple comparisons)
90-day mortalitySecondary55% (63/114)37% (83/226)Risk ratio 0.66 (95% CI 0.52-0.82)Not reported (not adjusted for multiple comparisons)
90-day mortalityAdverse37% thrombectomy vs 55% control (adjusted risk ratio 0.66, 95% CI 0.52-0.82)
7-day mortalityAdverse25% vs 33% (risk ratio 0.75, 95% CI 0.54-1.04)
Symptomatic intracranial hemorrhage (SITS-MOST) at 24-72hAdverse5% (12/226) thrombectomy vs 0% (0/114) control
Any intracranial hemorrhage (radiologic) at 24-72hAdverse14% (31/226) vs 2% (2/114) - risk ratio 8.13 (95% CI 1.98-33.4)
Procedural complicationsAdverse14% (32/226) in thrombectomy group - 6 arterial dissections, 5 vessel perforations, 1 fatal arterial perforation
Death from arterial perforationAdverse1 patient (thrombectomy group)

Subgroup Analysis

Primary outcome benefit consistent across most prespecified subgroups (Figure 3, Adjusted Rate Ratio, 95% CI): greater effect in patients with NIHSS ≥20 (adjusted rate ratio 3.53, 1.71-7.29) vs 10-19 (1.51, 1.05-2.18); proximal basilar occlusion (3.09, 1.45-6.58) showed larger effect than distal (1.33, 0.86-2.03, non-significant); benefit seen in patients with and without IV thrombolysis, and across age and sex subgroups; no correction for multiple comparisons.


Criticisms

  • Exclusively Chinese population; large-artery atherosclerosis was the stroke cause in approximately 44% overall (intracranial LAA specifically ~36%, 123/340) — results may not generalize to Western populations with predominantly embolic basilar occlusion.
  • Open-label design with unblinded treating teams; only outcome assessors were blinded.
  • Relatively low use of IV thrombolysis (~31-34% vs ~80% in BASICS) partly due to Chinese out-of-pocket payment requirements, which may have disadvantaged the control group.
  • Enrolled only patients with NIHSS ≥10; findings do not apply to milder posterior circulation stroke.
  • No correction for multiple comparisons on secondary outcomes — secondary and subgroup results are exploratory.
  • High rate of adjunctive angioplasty/stenting (40% intracranial, 8% extracranial) reflects local practice and may contribute to procedural complication rate.
  • 12-hour window; findings do not apply to later time windows (see BAOCHE trial for 6-24h).

Funding

Program for Innovative Research Team of the First Affiliated Hospital of the University of Science and Technology of China; Beijing Dingyi Foundation (China Special Fund for Stroke Prevention and Treatment); Beijing Healthunion Cardio-Cerebrovascular Disease Prevention and Treatment Foundation. Funders had no role in design/conduct/publication decision. ClinicalTrials.gov NCT04751708.

Based on: ATTENTION (New England Journal of Medicine, 2022)

Authors: Tao C, Nogueira RG, Zhu Y, et al. (ATTENTION Investigators)

Citation: N Engl J Med 2022;387:1361-1372

Content summarized and formatted by NeuroTrials.ai.